Status:
TERMINATED
Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane
Lead Sponsor:
Barnes Retina Institute
Collaborating Sponsors:
Allergan
Conditions:
Epiretinal Membrane
Macular Edema
Eligibility:
All Genders
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the effect of dexamethasone intravitreal implant (Ozurdex) in combination with pars plana vitrectomy and membrane peeling for idiopathic epiretinal membrane (E...
Detailed Description
Pars plana vitrectomy with membrane peeling has been used for years to successfully to treat ERM (epiretinal membrane). However, despite successful surgery, approximately 10-30% of patients may not ex...
Eligibility Criteria
Inclusion
- Patients with idiopathic epiretinal membrane
- Preoperative visual acuity of snellen equivalent 20/32 or worse
Exclusion
- History or presence of any of the following:
- uveitis
- macular hole
- previous vitreoretinal surgery
- any other retinal pathology that could affect anatomic or functional results
- Age Related Macular Degeneration
- Diabetic Retinopathy
- Diabetic Macular Edema
- Retinal Vein Occlusion
- Pre-existing Macular Disease
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01410201
Start Date
August 1 2011
End Date
January 1 2016
Last Update
July 27 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Lukes Hospital
Chesterfield, Missouri, United States, 63017
2
St. Louis Eye Surgery and Laser Center
St Louis, Missouri, United States, 63131
3
The Retina Institute
St Louis, Missouri, United States, 63144